GenScript Granted Authorization for cPass⢠SARS-CoV-2 Neutralization Antibody Detection Test in Brazil
World s first test capable of detecting virus-blocking antibodies that can be performed in standard labs in under an hour
cPass SARS-COV-2 neutralization antibody kit by GenScript Previous Next
Newswise PISCATAWAY, NEW JERSEY, December 14, 2020 – GenScript
USA Inc., the world’s leading research reagent provider, announced today that Brazil s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.